Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.

Antinori A, Meraviglia P, Monforte Ad, Castagna A, Mussini C, Bini T, Gianotti N, Rusconi S, Colella E, Airoldi G, Mancusi D, Termini R.

Drug Des Devel Ther. 2016 May 6;10:1589-603. doi: 10.2147/DDDT.S104875. eCollection 2016.

2.

HIV protease inhibitors: a review of molecular selectivity and toxicity.

Lv Z, Chu Y, Wang Y.

HIV AIDS (Auckl). 2015 Apr 8;7:95-104. doi: 10.2147/HIV.S79956. eCollection 2015. Review.

3.

Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):382-91. doi: 10.1097/QAI.0000000000000002.

4.

The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients.

Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ Jr, Hughes MD.

AIDS Res Hum Retroviruses. 2013 Apr;29(4):652-7. doi: 10.1089/AID.2012.0180. Epub 2013 Jan 9.

5.

Role of darunavir in the management of HIV infection.

Lascar RM, Benn P.

HIV AIDS (Auckl). 2009;1:31-9. Epub 2009 Nov 10.

6.

Hypersensitivity reactions to HIV therapy.

Chaponda M, Pirmohamed M.

Br J Clin Pharmacol. 2011 May;71(5):659-71. doi: 10.1111/j.1365-2125.2010.03784.x. Review.

7.

The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.

Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM.

HIV Clin Trials. 2010 Nov-Dec;11(6):351-8. doi: 10.1310/hct1106-351.

8.

Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.

Osih RB, Taffé P, Rickenbach M, Gayet-Ageron A, Elzi L, Fux C, Opravil M, Bernasconi E, Schmid P, Günthard HF, Cavassini M; Swiss HIV Cohort Study.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1239-46. doi: 10.1089/aid.2010.0070. Epub 2010 Oct 7.

9.

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K; GRACE (Gender, Race, And Clinical Experience) Study Group.

Ann Intern Med. 2010 Sep 21;153(6):349-57. doi: 10.7326/0003-4819-153-6-201009210-00002.

10.

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

Neely M, Kovacs A.

Ther Clin Risk Manag. 2009 Jun;5(3):595-615. Epub 2009 Aug 3.

11.

Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Sasková KG, Kozísek M, Rezácová P, Brynda J, Yashina T, Kagan RM, Konvalinka J.

J Virol. 2009 Sep;83(17):8810-8. doi: 10.1128/JVI.00451-09. Epub 2009 Jun 17.

12.

Combating HIV resistance - focus on darunavir.

Tremblay CL.

Ther Clin Risk Manag. 2008 Aug;4(4):759-66.

13.

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Moltó J, Santos JR, Pérez-Alvarez N, Cedeño S, Miranda C, Khoo S, Else L, Llibre JM, Valle M, Clotet B.

Antimicrob Agents Chemother. 2008 Nov;52(11):3928-32. doi: 10.1128/AAC.00520-08. Epub 2008 Aug 25.

Supplemental Content

Support Center